FOXO Technologies Subsidiary to Acquire Four Blood Collection Centers for $3.5M

summarizeSummary

FOXO Technologies' subsidiary Vector BioSource agreed to buy four blood collection centers from Grifols for $3.5 million cash plus up to $1 million in earn-outs, a deal that could transform the company but hinges on securing new regulatory licenses.

check_boxKey Events · M&A and Partnerships · FOXOD

• Acquisition of Four Blood Collection Centers

  Vector BioSource, a FOXO subsidiary, entered into an asset purchase agreement on July 22, 2026, to acquire four U.S. blood collection centers from Grifols Bio Supplies for $3.5 million cash at closing plus a contingent earn-out of up to $1 million.

• Earn-Out Tied to EBITDA Performance

  The full $1 million earn-out is payable if the acquired business generates EBITDA of $1.5 million or more in any single calendar year during 2026, 2027, or 2028.

• Regulatory Conditions to Closing

  Closing is conditioned on Vector obtaining a new FDA license, CLIA certification in Tennessee (and other applicable states), and a waste management permit from Miami city authorities, all independent of the seller's existing licenses.

• Expected Closing and Termination Rights

  The company anticipates closing in Q3 or Q4 2026, but either party may terminate the agreement if closing has not occurred within nine months (by April 22, 2027).

auto_awesomeAnalysis · FOXOD · Industrial Applications And Services

FOXO Technologies' subsidiary Vector BioSource is acquiring four U.S. blood collection centers from Grifols for $3.5 million cash plus a potential $1 million earn-out. This is a significant expansion for a company with a market cap around $62,000 — the deal value is roughly 56 times the company's market cap, representing a transformative acquisition. However, closing is contingent on Vector obtaining its own FDA license, CLIA certification, and a waste management permit, which introduces execution risk. The company expects to close in Q3 or Q4 2026, but either party can walk away if conditions aren't met within nine months. The acquisition could dramatically scale FOXO's biospecimen business, but the regulatory hurdles and the company's micro-cap status mean the market will likely view this as high-risk, high-reward.